BGBR 046
Alternative Names: BGBR-046Latest Information Update: 09 Aug 2024
At a glance
- Originator BeiGene
- Class Antineoplastics
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Jul 2024 Preclinical trials in Solid tumours in China (IV)
- 16 Jul 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease) in China (IV) (NCT06487858)
- 16 Jul 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (unspecified route) (NCT06487858)